The DETECT HCV Screening Trial
NCT04003454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 147533
Last updated 2025-02-06
Summary
The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency departments (EDs) across the United States (Aim 1 - "Screening Trial").
Conditions
- Hepatitis C
Interventions
- OTHER
-
HCV Screening
The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
Sponsors & Collaborators
- collaborator OTHER
-
University of Mississippi Medical Center
collaborator OTHER -
Boston University
collaborator OTHER -
Boston Medical Center
collaborator OTHER -
University of Cincinnati
collaborator OTHER -
Alameda County Medical Center
collaborator OTHER -
Denver Health and Hospital Authority
lead OTHER
Principal Investigators
-
Jason Haukoos, MD, MSc · Denver Health
-
Sarah Rowan, MD · Denver Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-20
- Primary Completion
- 2023-07-31
- Completion
- 2024-01-31
Countries
- United States
Study Locations
More Related Trials
-
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
NCT02309450 ·Status: WITHDRAWN ·Phase: PHASE2
-
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
NCT03119025 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
NCT03244371 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside
NCT03513796 ·Status: COMPLETED
-
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
NCT00663208 ·Status: COMPLETED ·Phase: PHASE2
-
Early Detection of HCV in Injection Drug Users
NCT06431945 ·Status: RECRUITING
-
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
NCT04019717 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
NCT04405024 ·Status: SUSPENDED ·Phase: NA
-
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
NCT03603327 ·Status: COMPLETED ·Phase: NA
-
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
NCT04768517 ·Status: UNKNOWN
-
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02333292 ·Status: COMPLETED
-
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
NCT01979939 ·Status: COMPLETED ·Phase: PHASE3
-
Qualification of Point-of-Care Assays for Management of HCV Patients
NCT02335320 ·Status: UNKNOWN
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
NCT06409169 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)
NCT01554189 ·Status: TERMINATED ·Phase: PHASE1
-
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
NCT01973049 ·Status: COMPLETED ·Phase: PHASE3
-
Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment
NCT03480269 ·Status: UNKNOWN
-
Long-term Follow-up of HALT-C Sustained Virological Responders
NCT00825877 ·Status: COMPLETED
-
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
NCT04971330 ·Status: COMPLETED
-
Rapid HCV Treatment Access for Persons Who Use Drugs
NCT04677153 ·Status: COMPLETED ·Phase: NA
-
Eliminating Hepatitis C Virus
NCT03401697 ·Status: COMPLETED
-
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
NCT01257204 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
NCT03593447 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
NCT01842451 ·Status: COMPLETED ·Phase: PHASE2
-
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953 ·Status: COMPLETED ·Phase: PHASE3